` Comparison: NKTX vs USBC - Alpha Spread

NKTX
vs
U
USBC

Over the past 12 months, NKTX has underperformed USBC, delivering a return of +38% compared to the USBC's +429 900% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
NKTX
USBC
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

NKTX Intrinsic Value
HIDDEN
Show
USBC Intrinsic Value
HIDDEN
Show
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
Nkarta Inc
NASDAQ:NKTX
2.48 USD
U
US BioTec Inc
OTC:USBC
0.43 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
NKTX, USBC

NKTX
USBC
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Nkarta Inc
Revenue
U
US BioTec Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
NKTX, USBC

NKTX
USBC
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Nkarta Inc
NASDAQ:NKTX
U
US BioTec Inc
OTC:USBC
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

NKTX
0%
USBC
0%
LTM 3Y Avg 5Y Avg 10Y Avg
Nkarta Inc
U
US BioTec Inc

Operating Margin

NKTX
0%
USBC
0%
LTM 3Y Avg 5Y Avg 10Y Avg
Nkarta Inc
U
US BioTec Inc

Net Margin

NKTX
0%
USBC
0%
LTM 3Y Avg 5Y Avg 10Y Avg
Nkarta Inc
U
US BioTec Inc

FCF Margin

NKTX
0%
USBC
0%
LTM 3Y Avg 5Y Avg 10Y Avg
Nkarta Inc
U
US BioTec Inc

ROE

NKTX
-26.7%
USBC
-51.3%
LTM 3Y Avg 5Y Avg 10Y Avg
Nkarta Inc
U
US BioTec Inc

ROA

NKTX
-21.4%
USBC
-37.8%
LTM 3Y Avg 5Y Avg 10Y Avg
Nkarta Inc
U
US BioTec Inc

ROIC

NKTX
-62.5%
USBC
-31.3%
LTM 3Y Avg 5Y Avg 10Y Avg
Nkarta Inc
U
US BioTec Inc

ROCE

NKTX
-26.6%
USBC
-30.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Nkarta Inc
U
US BioTec Inc

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
NKTX, USBC

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
NKTX, USBC

Performance Gap Between NKTX and USBC
HIDDEN
Show

Performance By Year
NKTX, USBC

Loading
NKTX
USBC
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare NKTX to other stocks
PNEXF
Pharnext SCA
ABBV
Abbvie Inc
ATXS
Astria Therapeutics Inc
AMGN
Amgen Inc
Custom
Choose any stock
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett